[
  {
    "ts": null,
    "headline": "RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA",
    "summary": "mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts Milan, 29 January 2026 – Recordati today announced that it has entered into a collaboration and license agreement with Moderna to",
    "url": "https://finnhub.io/api/news?id=673f97504815272182c46895334b5a732fa695f582de2aa75039d4eb4e2b34a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769725200,
      "headline": "RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA",
      "id": 138301208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts Milan, 29 January 2026 – Recordati today announced that it has entered into a collaboration and license agreement with Moderna to",
      "url": "https://finnhub.io/api/news?id=673f97504815272182c46895334b5a732fa695f582de2aa75039d4eb4e2b34a4"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)",
    "summary": "Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties ...",
    "url": "https://finnhub.io/api/news?id=2b6dd1116631783f61ac7643406931fea1a0300b531709b67fdad2a0be57dbea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769724000,
      "headline": "Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)",
      "id": 138300264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties ...",
      "url": "https://finnhub.io/api/news?id=2b6dd1116631783f61ac7643406931fea1a0300b531709b67fdad2a0be57dbea"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Moderna: “We Have to Wait and See”",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a cancer vaccination, a caller asked if they should invest in the stock. Cramer replied: Well, I gotta tell you, this is something that they did promise a long time ago, and I hope […]",
    "url": "https://finnhub.io/api/news?id=a775ab079d155a8eb2f24f7f8e364f02b984181686c0b36b6cd57a864b070829",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769717380,
      "headline": "Jim Cramer on Moderna: “We Have to Wait and See”",
      "id": 138300265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a cancer vaccination, a caller asked if they should invest in the stock. Cramer replied: Well, I gotta tell you, this is something that they did promise a long time ago, and I hope […]",
      "url": "https://finnhub.io/api/news?id=a775ab079d155a8eb2f24f7f8e364f02b984181686c0b36b6cd57a864b070829"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance",
    "summary": "Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and co-develop late-stage experimental vaccines, including programs for Epstein Barr virus and herpes simplex virus. This adjustment marks a change in how Moderna plans to advance its mRNA pipeline and share risk on large, expensive studies. Moderna is best known for its mRNA based vaccines, and it...",
    "url": "https://finnhub.io/api/news?id=0a7e01763a2755090a4a7e8f7b4996ad806ac31117173aa60a0c159e6c636e33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769717301,
      "headline": "Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance",
      "id": 138300266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and co-develop late-stage experimental vaccines, including programs for Epstein Barr virus and herpes simplex virus. This adjustment marks a change in how Moderna plans to advance its mRNA pipeline and share risk on large, expensive studies. Moderna is best known for its mRNA based vaccines, and it...",
      "url": "https://finnhub.io/api/news?id=0a7e01763a2755090a4a7e8f7b4996ad806ac31117173aa60a0c159e6c636e33"
    }
  },
  {
    "ts": null,
    "headline": "Moderna holds a ‘garage sale’; Roche defends obesity drug data",
    "summary": "Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA decision date.",
    "url": "https://finnhub.io/api/news?id=c04ed339fe7961afc6c1baff43dac33bcafca111f23048f74d307bea817c05de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769682000,
      "headline": "Moderna holds a ‘garage sale’; Roche defends obesity drug data",
      "id": 138306135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA decision date.",
      "url": "https://finnhub.io/api/news?id=c04ed339fe7961afc6c1baff43dac33bcafca111f23048f74d307bea817c05de"
    }
  },
  {
    "ts": null,
    "headline": "This Stock Is Already Up 58% This Year. Is It a Buy?",
    "summary": "This forgotten pandemic stock hasn't said its last word.",
    "url": "https://finnhub.io/api/news?id=7d3b4aafebd541940f4ab91d6e663aae518166cef14fe261f77adcbbdf0e0d20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769652300,
      "headline": "This Stock Is Already Up 58% This Year. Is It a Buy?",
      "id": 138291630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "This forgotten pandemic stock hasn't said its last word.",
      "url": "https://finnhub.io/api/news?id=7d3b4aafebd541940f4ab91d6e663aae518166cef14fe261f77adcbbdf0e0d20"
    }
  }
]